Genetic differences & Alzheimer's disease
Posted: Thu Feb 15, 2018 7:29 am
An example:
http://europepmc.org/abstract/MED/24755620
Sub-networks (SNs) involved in glutamate signaling were significantly overrepresented in Alzheimer's.
This is just one example. A list of genome-wide association studies can be found here:
http://www.ebi.ac.uk/gwas/search?query=Alzheimer
Two homozygous APOE4 carriers might show different outcomes, in terms of eventual AD, even when they adopt identical practices. Therefore studies with small numbers are not reliable predictors of eventual outcomes in a given individual.
Large-scale trials are more likely to be applicable to a given individual, since SNPs and networks of SNPs are more likely to be randomly distributed in larger populations.
What does this mean for daily life?
Rely more on large-scale studies and genome-wide associations, less on anecdotal evidence or small-scale studies.
Rely more on studies of health outcomes (disability or mortality) than studies of biomarkers, because the biomarkers used are only a subset of the relevant biomarkers and interactions (known and unknown).
Keep making a good day and a good week, because your efforts will be rewarded more surely than if you worry obsessively about life in future decades. Besides, excessive worry increases cortisol levels. Expand your horizons to include all that makes health worth having and life worth living.
Of course, as genome-wide analysis becomes more commonplace, we'll have increasingly better information about what interventions will work best for each individual. The future seems rosier because of our constantly expanding knowledge.
http://europepmc.org/abstract/MED/24755620
Sub-networks (SNs) involved in glutamate signaling were significantly overrepresented in Alzheimer's.
This is just one example. A list of genome-wide association studies can be found here:
http://www.ebi.ac.uk/gwas/search?query=Alzheimer
Two homozygous APOE4 carriers might show different outcomes, in terms of eventual AD, even when they adopt identical practices. Therefore studies with small numbers are not reliable predictors of eventual outcomes in a given individual.
Large-scale trials are more likely to be applicable to a given individual, since SNPs and networks of SNPs are more likely to be randomly distributed in larger populations.
What does this mean for daily life?
Rely more on large-scale studies and genome-wide associations, less on anecdotal evidence or small-scale studies.
Rely more on studies of health outcomes (disability or mortality) than studies of biomarkers, because the biomarkers used are only a subset of the relevant biomarkers and interactions (known and unknown).
Keep making a good day and a good week, because your efforts will be rewarded more surely than if you worry obsessively about life in future decades. Besides, excessive worry increases cortisol levels. Expand your horizons to include all that makes health worth having and life worth living.
Of course, as genome-wide analysis becomes more commonplace, we'll have increasingly better information about what interventions will work best for each individual. The future seems rosier because of our constantly expanding knowledge.